# Advanced NanoTherapies

> Advanced NanoTherapies is a clinical-stage medical device company developing SirPlux Duo, an investigational drug-coated balloon that delivers sirolimus and paclitaxel through biodegradable nanoparticles licensed from Cleveland Clinic. It targets coronary and peripheral artery disease without leaving a permanent implant.

- **Founded:** 2018
- **Headquarters:** Santa Clara, United States
- **Founders:** Marwan Berrada-Sounni (Co-founder and CEO), Mehdi Shishehbor (Co-founder; identified as Chief Medical Officer in 2020 and 2022 releases), Philippe Urbain (Co-founder; listed by Crunchbase)
- **Products:** SirPlux Duo Drug-Coated Balloon, Functionalized nanoparticle delivery platform
- **Notable:** Exclusive Cleveland Clinic technology license in 2019., Reported FDA Breakthrough Device designations covering small-vessel coronary disease, coronary in-stent restenosis and below-the-knee peripheral lesions., First cohort of ten patients treated in ADVANCE-DCB by August 2023.

## Products & services

- **SirPlux Duo Drug-Coated Balloon** — Investigational catheter-based balloon delivering sirolimus and paclitaxel simultaneously using biodegradable functionalized nanoparticles; being studied for coronary lesions and developed for below-the-knee peripheral disease.
- **Functionalized nanoparticle delivery platform** — Drug-agnostic, biodegradable drug delivery technology exclusively licensed from Cleveland Clinic in 2019; basis for SirPlux Duo and potential future applications.

## Achievements

- Exclusive Cleveland Clinic technology license in 2019.
- Reported FDA Breakthrough Device designations covering small-vessel coronary disease, coronary in-stent restenosis and below-the-knee peripheral lesions.
- First cohort of ten patients treated in ADVANCE-DCB by August 2023.
- Positive first-in-human findings announced in October 2024.
- More than $31 million Series B announced June 2026.

## Latest updates

- **2026-06** — Announced more than $31 million Series B; priorities include manufacturing scale-up, U.S. IDE submissions, coronary pivotal development and a below-the-knee early feasibility program.
- **2026-01** — ADVANCE-DUO registry posted: estimated 30 participants, single-group open-label design, Spanish sites and a 12-month target lesion failure primary endpoint.

## Links

- Website: https://advancednanotherapies.com/
- LinkedIn: https://www.linkedin.com/company/advanced-nanotherapies/

---

Profile page: https://yespress.io/advanced-nanotherapies
Published by YesPress — https://yespress.io
Last updated: 2026-10-03